Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by MrMugsyon Apr 18, 2022 12:38pm
136 Views
Post# 34610269

RE:RE:RE:Management Information Circular ...

RE:RE:RE:Management Information Circular ...
EbbFlow88 wrote: It's an advantage for all of us but I don't think they are trying to keep it down. 


Agreed - nature of the beast with ~70% of the shares in 270 hands.
The base of owners hasn't really changed.

-----------------------

Here's the kind of scenario I'd be expecting over the next 5 years ...
- purchase a few small drug portfolios for ROW or just a bunch of individual ROW drugs.
- Novartis to pay close attention to GUD/EXELON as they rate GUD's abilities with ROW (remember there is a very large agreement between the two but it is mostly redacted).
- Novartis (or other) to strike a deal ... trade a larger portfolio of ROW drugs for a percent of Knight.

Just my opinion.
<< Previous
Bullboard Posts
Next >>